Evidence map›Paper›PMID 41996252›Full record

ArticlemAbs2026

Multi-modal feature learning to prioritize ADCs with favorable half-life in mice.

Xiang-Wei Zhu, Khushboo Jani, Wenjia Gu, Mia Guterman, Valery R Polyakov, Hans-Peter Gerber, Werner Rubas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiang-Wei ZhuDepartment of Preclinical Development, Sutro Biopharma, South San Francisco, CA, USA.ORCID 0000-0002-1894-7679
Khushboo JaniDepartment of Preclinical Development, Sutro Biopharma, South San Francisco, CA, USA.
Wenjia GuDepartment of Preclinical Development, Sutro Biopharma, South San Francisco, CA, USA.
Mia GutermanDepartment of Preclinical Development, Sutro Biopharma, South San Francisco, CA, USA.
Valery R PolyakovDepartment of Preclinical Development, Sutro Biopharma, South San Francisco, CA, USA.
Hans-Peter GerberDepartment of Preclinical Development, Sutro Biopharma, South San Francisco, CA, USA.
Werner RubasDepartment of Preclinical Development, Sutro Biopharma, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Favorable pharmacokinetic (PK) properties of antibody-drug conjugates (ADCs) enable higher systemic exposure and are associated with improved clinical efficacy, yet ADC PK optimization remains largely empirical and resource-intensive. We developed an

Indexed as

Antibodies, MonoclonalImmunoconjugatesMachine LearningAnimalsHalf-LifeHumansMiceMice, Inbred C57BLAntibodies, MonoclonalImmunoconjugatesAlphaFold MultimerAntibody-drug conjugatespharmacokineticspreclinical developmentprotein language model

Identifiers

PMID41996252
PMCPMC13094291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.